M
Mark Hynes
Researcher at University of Michigan
Publications - 11
Citations - 1815
Mark Hynes is an academic researcher from University of Michigan. The author has contributed to research in topics: Cancer stem cell & Cancer. The author has an hindex of 8, co-authored 11 publications receiving 1687 citations.
Papers
More filters
Journal ArticleDOI
Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.
Emina Huang,Mark Hynes,Tao Zhang,Tao Zhang,Christophe Ginestier,Gabriela Dontu,Henry D. Appelman,Jeremy Z. Fields,Max S. Wicha,Bruce M. Boman +9 more
TL;DR: The findings of this work support the original hypothesis, derived previously from mathematical modeling of crypt dynamics, that progressive colonic SC overpopulation occurs during colon tumorigenesis and drives CRC development.
Journal ArticleDOI
c-Met is a marker of pancreatic cancer stem cells and therapeutic target.
Chenwei Li,Jing Jiang Wu,Mark Hynes,Joseph Dosch,Bedabrata Sarkar,Theodore H. Welling,Marina Pasca di Magliano,Diane M. Simeone +7 more
TL;DR: In pancreatic tumors established in NOD SCID mice, c-Met inhibitors slowed tumor growth and reduced the population of CSCs when given alone or in combination with gemcitabine.
Journal ArticleDOI
Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer.
Joseph E. Carpentino,Mark Hynes,Henry D. Appelman,Tong Zheng,Dennis A. Steindler,Edward W. Scott,Emina Huang +6 more
TL;DR: Data link colitis and cancer identifying potential tumor-initiating cells from colitic patients, suggesting that sphere and/or xenograft formation will be useful to survey colitis patients at risk of developing cancer.
Journal ArticleDOI
The Notch Pathway Is Important in Maintaining the Cancer Stem Cell Population in Pancreatic Cancer
Ethan V. Abel,Edward J. Kim,Jingjiang Wu,Mark Hynes,Filip Bednar,Erica Proctor,Lidong Wang,Michele L. Dziubinski,Diane M. Simeone +8 more
TL;DR: The Notch signaling pathway is important in maintaining the pancreatic CSC population and is a potential therapeutic target in pancreatic cancer.
Journal ArticleDOI
Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
Wan-Ching Yen,Marcus Fischer,Mark Hynes,Jingjiang Wu,Edward J. Kim,Lucia Beviglia,V. Pete Yeung,Xiaomei Song,Ann M. Kapoun,John Lewicki,Austin L. Gurney,Diane M. Simeone,Timothy Hoey +12 more
TL;DR: The findings suggest a novel therapeutic approach for pancreatic cancer treatment through antagonism of DLL4/Notch signaling, which is efficacious in a broad spectrum of pancreatic tumor xenografts and showed additive antitumor activity together with gemcitabine.